img

Global Human Tuberculosis Vaccine Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Human Tuberculosis Vaccine Market Insights, Forecast to 2034

Global Human Tuberculosis Vaccine market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Human Tuberculosis Vaccine industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Human Tuberculosis Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Human Tuberculosis Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


GlaxoSmithKline
Merck
Serum Institute of India
Valneva
Archivel Farma
BIOFABRI (Zendal)
Japan BCG Laboratory
GreenSignal Bio Pharma
AJ Vaccines
Taj Pharma India
Biomed Lublin
Segment by Type
Intradermal
Percutaneous

Segment by Application


Pediatrics
Adults

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Human Tuberculosis Vaccine plant distribution, commercial date of Human Tuberculosis Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Human Tuberculosis Vaccine introduction, etc. Human Tuberculosis Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Human Tuberculosis Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Human Tuberculosis Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Human Tuberculosis Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Intradermal
1.2.3 Percutaneous
1.3 Market by Application
1.3.1 Global Human Tuberculosis Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Pediatrics
1.3.3 Adults
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Tuberculosis Vaccine Sales Estimates and Forecasts 2018-2029
2.2 Global Human Tuberculosis Vaccine Revenue by Region
2.2.1 Global Human Tuberculosis Vaccine Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Human Tuberculosis Vaccine Revenue by Region (2018-2024)
2.2.3 Global Human Tuberculosis Vaccine Revenue by Region (2024-2029)
2.2.4 Global Human Tuberculosis Vaccine Revenue Market Share by Region (2018-2029)
2.3 Global Human Tuberculosis Vaccine Sales Estimates and Forecasts 2018-2029
2.4 Global Human Tuberculosis Vaccine Sales by Region
2.4.1 Global Human Tuberculosis Vaccine Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Human Tuberculosis Vaccine Sales by Region (2018-2024)
2.4.3 Global Human Tuberculosis Vaccine Sales by Region (2024-2029)
2.4.4 Global Human Tuberculosis Vaccine Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Human Tuberculosis Vaccine Sales by Manufacturers
3.1.1 Global Human Tuberculosis Vaccine Sales by Manufacturers (2018-2024)
3.1.2 Global Human Tuberculosis Vaccine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Tuberculosis Vaccine in 2022
3.2 Global Human Tuberculosis Vaccine Revenue by Manufacturers
3.2.1 Global Human Tuberculosis Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Human Tuberculosis Vaccine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Human Tuberculosis Vaccine Revenue in 2022
3.3 Global Key Players of Human Tuberculosis Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Human Tuberculosis Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Human Tuberculosis Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Human Tuberculosis Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Human Tuberculosis Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Human Tuberculosis Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Human Tuberculosis Vaccine Sales by Type
4.1.1 Global Human Tuberculosis Vaccine Historical Sales by Type (2018-2024)
4.1.2 Global Human Tuberculosis Vaccine Forecasted Sales by Type (2024-2029)
4.1.3 Global Human Tuberculosis Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Human Tuberculosis Vaccine Revenue by Type
4.2.1 Global Human Tuberculosis Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Human Tuberculosis Vaccine Forecasted Revenue by Type (2024-2029)
4.2.3 Global Human Tuberculosis Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Human Tuberculosis Vaccine Price by Type
4.3.1 Global Human Tuberculosis Vaccine Price by Type (2018-2024)
4.3.2 Global Human Tuberculosis Vaccine Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Human Tuberculosis Vaccine Sales by Application
5.1.1 Global Human Tuberculosis Vaccine Historical Sales by Application (2018-2024)
5.1.2 Global Human Tuberculosis Vaccine Forecasted Sales by Application (2024-2029)
5.1.3 Global Human Tuberculosis Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Human Tuberculosis Vaccine Revenue by Application
5.2.1 Global Human Tuberculosis Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Human Tuberculosis Vaccine Forecasted Revenue by Application (2024-2029)
5.2.3 Global Human Tuberculosis Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Human Tuberculosis Vaccine Price by Application
5.3.1 Global Human Tuberculosis Vaccine Price by Application (2018-2024)
5.3.2 Global Human Tuberculosis Vaccine Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Human Tuberculosis Vaccine Market Size by Type
6.1.1 US & Canada Human Tuberculosis Vaccine Sales by Type (2018-2029)
6.1.2 US & Canada Human Tuberculosis Vaccine Revenue by Type (2018-2029)
6.2 US & Canada Human Tuberculosis Vaccine Market Size by Application
6.2.1 US & Canada Human Tuberculosis Vaccine Sales by Application (2018-2029)
6.2.2 US & Canada Human Tuberculosis Vaccine Revenue by Application (2018-2029)
6.3 US & Canada Human Tuberculosis Vaccine Market Size by Country
6.3.1 US & Canada Human Tuberculosis Vaccine Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Human Tuberculosis Vaccine Sales by Country (2018-2029)
6.3.3 US & Canada Human Tuberculosis Vaccine Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Human Tuberculosis Vaccine Market Size by Type
7.1.1 Europe Human Tuberculosis Vaccine Sales by Type (2018-2029)
7.1.2 Europe Human Tuberculosis Vaccine Revenue by Type (2018-2029)
7.2 Europe Human Tuberculosis Vaccine Market Size by Application
7.2.1 Europe Human Tuberculosis Vaccine Sales by Application (2018-2029)
7.2.2 Europe Human Tuberculosis Vaccine Revenue by Application (2018-2029)
7.3 Europe Human Tuberculosis Vaccine Market Size by Country
7.3.1 Europe Human Tuberculosis Vaccine Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Human Tuberculosis Vaccine Sales by Country (2018-2029)
7.3.3 Europe Human Tuberculosis Vaccine Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Human Tuberculosis Vaccine Market Size
8.1.1 China Human Tuberculosis Vaccine Sales (2018-2029)
8.1.2 China Human Tuberculosis Vaccine Revenue (2018-2029)
8.2 China Human Tuberculosis Vaccine Market Size by Application
8.2.1 China Human Tuberculosis Vaccine Sales by Application (2018-2029)
8.2.2 China Human Tuberculosis Vaccine Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Human Tuberculosis Vaccine Market Size by Type
9.1.1 Asia Human Tuberculosis Vaccine Sales by Type (2018-2029)
9.1.2 Asia Human Tuberculosis Vaccine Revenue by Type (2018-2029)
9.2 Asia Human Tuberculosis Vaccine Market Size by Application
9.2.1 Asia Human Tuberculosis Vaccine Sales by Application (2018-2029)
9.2.2 Asia Human Tuberculosis Vaccine Revenue by Application (2018-2029)
9.3 Asia Human Tuberculosis Vaccine Sales by Region
9.3.1 Asia Human Tuberculosis Vaccine Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Human Tuberculosis Vaccine Revenue by Region (2018-2029)
9.3.3 Asia Human Tuberculosis Vaccine Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Human Tuberculosis Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Human Tuberculosis Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Information
11.1.2 GlaxoSmithKline Overview
11.1.3 GlaxoSmithKline Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 GlaxoSmithKline Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GlaxoSmithKline Recent Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Overview
11.2.3 Merck Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Merck Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 Serum Institute of India
11.3.1 Serum Institute of India Company Information
11.3.2 Serum Institute of India Overview
11.3.3 Serum Institute of India Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Serum Institute of India Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Serum Institute of India Recent Developments
11.4 Valneva
11.4.1 Valneva Company Information
11.4.2 Valneva Overview
11.4.3 Valneva Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Valneva Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Valneva Recent Developments
11.5 Archivel Farma
11.5.1 Archivel Farma Company Information
11.5.2 Archivel Farma Overview
11.5.3 Archivel Farma Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Archivel Farma Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Archivel Farma Recent Developments
11.6 BIOFABRI (Zendal)
11.6.1 BIOFABRI (Zendal) Company Information
11.6.2 BIOFABRI (Zendal) Overview
11.6.3 BIOFABRI (Zendal) Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 BIOFABRI (Zendal) Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 BIOFABRI (Zendal) Recent Developments
11.7 Japan BCG Laboratory
11.7.1 Japan BCG Laboratory Company Information
11.7.2 Japan BCG Laboratory Overview
11.7.3 Japan BCG Laboratory Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Japan BCG Laboratory Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Japan BCG Laboratory Recent Developments
11.8 GreenSignal Bio Pharma
11.8.1 GreenSignal Bio Pharma Company Information
11.8.2 GreenSignal Bio Pharma Overview
11.8.3 GreenSignal Bio Pharma Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 GreenSignal Bio Pharma Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 GreenSignal Bio Pharma Recent Developments
11.9 AJ Vaccines
11.9.1 AJ Vaccines Company Information
11.9.2 AJ Vaccines Overview
11.9.3 AJ Vaccines Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 AJ Vaccines Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 AJ Vaccines Recent Developments
11.10 Taj Pharma India
11.10.1 Taj Pharma India Company Information
11.10.2 Taj Pharma India Overview
11.10.3 Taj Pharma India Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Taj Pharma India Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Taj Pharma India Recent Developments
11.11 Biomed Lublin
11.11.1 Biomed Lublin Company Information
11.11.2 Biomed Lublin Overview
11.11.3 Biomed Lublin Human Tuberculosis Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Biomed Lublin Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Biomed Lublin Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Human Tuberculosis Vaccine Industry Chain Analysis
12.2 Human Tuberculosis Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Tuberculosis Vaccine Production Mode & Process
12.4 Human Tuberculosis Vaccine Sales and Marketing
12.4.1 Human Tuberculosis Vaccine Sales Channels
12.4.2 Human Tuberculosis Vaccine Distributors
12.5 Human Tuberculosis Vaccine Customers
13 Market Dynamics
13.1 Human Tuberculosis Vaccine Industry Trends
13.2 Human Tuberculosis Vaccine Market Drivers
13.3 Human Tuberculosis Vaccine Market Challenges
13.4 Human Tuberculosis Vaccine Market Restraints
14 Key Findings in The Global Human Tuberculosis Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Human Tuberculosis Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Intradermal
Table 3. Major Manufacturers of Percutaneous
Table 4. Global Human Tuberculosis Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Human Tuberculosis Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Human Tuberculosis Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Human Tuberculosis Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Human Tuberculosis Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Human Tuberculosis Vaccine Revenue Market Share by Region (2024-2029)
Table 10. Global Human Tuberculosis Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Human Tuberculosis Vaccine Sales by Region (2018-2024) & (K Units)
Table 12. Global Human Tuberculosis Vaccine Sales by Region (2024-2029) & (K Units)
Table 13. Global Human Tuberculosis Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Human Tuberculosis Vaccine Sales Market Share by Region (2024-2029)
Table 15. Global Human Tuberculosis Vaccine Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Human Tuberculosis Vaccine Sales Share by Manufacturers (2018-2024)
Table 17. Global Human Tuberculosis Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Human Tuberculosis Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Human Tuberculosis Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Human Tuberculosis Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Human Tuberculosis Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Human Tuberculosis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Tuberculosis Vaccine as of 2022)
Table 23. Global Key Manufacturers of Human Tuberculosis Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Human Tuberculosis Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Human Tuberculosis Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Human Tuberculosis Vaccine Sales by Type (2018-2024) & (K Units)
Table 28. Global Human Tuberculosis Vaccine Sales by Type (2024-2029) & (K Units)
Table 29. Global Human Tuberculosis Vaccine Sales Share by Type (2018-2024)
Table 30. Global Human Tuberculosis Vaccine Sales Share by Type (2024-2029)
Table 31. Global Human Tuberculosis Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Human Tuberculosis Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Human Tuberculosis Vaccine Revenue Share by Type (2018-2024)
Table 34. Global Human Tuberculosis Vaccine Revenue Share by Type (2024-2029)
Table 35. Human Tuberculosis Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Human Tuberculosis Vaccine Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global Human Tuberculosis Vaccine Sales by Application (2018-2024) & (K Units)
Table 38. Global Human Tuberculosis Vaccine Sales by Application (2024-2029) & (K Units)
Table 39. Global Human Tuberculosis Vaccine Sales Share by Application (2018-2024)
Table 40. Global Human Tuberculosis Vaccine Sales Share by Application (2024-2029)
Table 41. Global Human Tuberculosis Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Human Tuberculosis Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Human Tuberculosis Vaccine Revenue Share by Application (2018-2024)
Table 44. Global Human Tuberculosis Vaccine Revenue Share by Application (2024-2029)
Table 45. Human Tuberculosis Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Human Tuberculosis Vaccine Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada Human Tuberculosis Vaccine Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Human Tuberculosis Vaccine Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Human Tuberculosis Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Human Tuberculosis Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Human Tuberculosis Vaccine Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Human Tuberculosis Vaccine Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Human Tuberculosis Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Human Tuberculosis Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Human Tuberculosis Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Human Tuberculosis Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Human Tuberculosis Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Human Tuberculosis Vaccine Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Human Tuberculosis Vaccine Sales by Country (2024-2029) & (K Units)
Table 60. Europe Human Tuberculosis Vaccine Sales by Type (2018-2024) & (K Units)
Table 61. Europe Human Tuberculosis Vaccine Sales by Type (2024-2029) & (K Units)
Table 62. Europe Human Tuberculosis Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Human Tuberculosis Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Human Tuberculosis Vaccine Sales by Application (2018-2024) & (K Units)
Table 65. Europe Human Tuberculosis Vaccine Sales by Application (2024-2029) & (K Units)
Table 66. Europe Human Tuberculosis Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Human Tuberculosis Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Human Tuberculosis Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Human Tuberculosis Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Human Tuberculosis Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Human Tuberculosis Vaccine Sales by Country (2018-2024) & (K Units)
Table 72. Europe Human Tuberculosis Vaccine Sales by Country (2024-2029) & (K Units)
Table 73. China Human Tuberculosis Vaccine Sales by Type (2018-2024) & (K Units)
Table 74. China Human Tuberculosis Vaccine Sales by Type (2024-2029) & (K Units)
Table 75. China Human Tuberculosis Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Human Tuberculosis Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Human Tuberculosis Vaccine Sales by Application (2018-2024) & (K Units)
Table 78. China Human Tuberculosis Vaccine Sales by Application (2024-2029) & (K Units)
Table 79. China Human Tuberculosis Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Human Tuberculosis Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Human Tuberculosis Vaccine Sales by Type (2018-2024) & (K Units)
Table 82. Asia Human Tuberculosis Vaccine Sales by Type (2024-2029) & (K Units)
Table 83. Asia Human Tuberculosis Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Human Tuberculosis Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Human Tuberculosis Vaccine Sales by Application (2018-2024) & (K Units)
Table 86. Asia Human Tuberculosis Vaccine Sales by Application (2024-2029) & (K Units)
Table 87. Asia Human Tuberculosis Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Human Tuberculosis Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Human Tuberculosis Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Human Tuberculosis Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Human Tuberculosis Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Human Tuberculosis Vaccine Sales by Region (2018-2024) & (K Units)
Table 93. Asia Human Tuberculosis Vaccine Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales by Country (2024-2029) & (K Units)
Table 107. GlaxoSmithKline Company Information
Table 108. GlaxoSmithKline Description and Major Businesses
Table 109. GlaxoSmithKline Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. GlaxoSmithKline Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. GlaxoSmithKline Recent Developments
Table 112. Merck Company Information
Table 113. Merck Description and Major Businesses
Table 114. Merck Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Merck Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Merck Recent Developments
Table 117. Serum Institute of India Company Information
Table 118. Serum Institute of India Description and Major Businesses
Table 119. Serum Institute of India Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Serum Institute of India Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Serum Institute of India Recent Developments
Table 122. Valneva Company Information
Table 123. Valneva Description and Major Businesses
Table 124. Valneva Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Valneva Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Valneva Recent Developments
Table 127. Archivel Farma Company Information
Table 128. Archivel Farma Description and Major Businesses
Table 129. Archivel Farma Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Archivel Farma Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Archivel Farma Recent Developments
Table 132. BIOFABRI (Zendal) Company Information
Table 133. BIOFABRI (Zendal) Description and Major Businesses
Table 134. BIOFABRI (Zendal) Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. BIOFABRI (Zendal) Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. BIOFABRI (Zendal) Recent Developments
Table 137. Japan BCG Laboratory Company Information
Table 138. Japan BCG Laboratory Description and Major Businesses
Table 139. Japan BCG Laboratory Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Japan BCG Laboratory Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Japan BCG Laboratory Recent Developments
Table 142. GreenSignal Bio Pharma Company Information
Table 143. GreenSignal Bio Pharma Description and Major Businesses
Table 144. GreenSignal Bio Pharma Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. GreenSignal Bio Pharma Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. GreenSignal Bio Pharma Recent Developments
Table 147. AJ Vaccines Company Information
Table 148. AJ Vaccines Description and Major Businesses
Table 149. AJ Vaccines Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. AJ Vaccines Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. AJ Vaccines Recent Developments
Table 152. Taj Pharma India Company Information
Table 153. Taj Pharma India Description and Major Businesses
Table 154. Taj Pharma India Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Taj Pharma India Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Taj Pharma India Recent Developments
Table 157. Biomed Lublin Company Information
Table 158. Biomed Lublin Description and Major Businesses
Table 159. Biomed Lublin Human Tuberculosis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. Biomed Lublin Human Tuberculosis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Biomed Lublin Recent Developments
Table 162. Key Raw Materials Lists
Table 163. Raw Materials Key Suppliers Lists
Table 164. Human Tuberculosis Vaccine Distributors List
Table 165. Human Tuberculosis Vaccine Customers List
Table 166. Human Tuberculosis Vaccine Market Trends
Table 167. Human Tuberculosis Vaccine Market Drivers
Table 168. Human Tuberculosis Vaccine Market Challenges
Table 169. Human Tuberculosis Vaccine Market Restraints
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Tuberculosis Vaccine Product Picture
Figure 2. Global Human Tuberculosis Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Human Tuberculosis Vaccine Market Share by Type in 2022 & 2029
Figure 4. Intradermal Product Picture
Figure 5. Percutaneous Product Picture
Figure 6. Global Human Tuberculosis Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Human Tuberculosis Vaccine Market Share by Application in 2022 & 2029
Figure 8. Pediatrics
Figure 9. Adults
Figure 10. Human Tuberculosis Vaccine Report Years Considered
Figure 11. Global Human Tuberculosis Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Human Tuberculosis Vaccine Revenue 2018-2029 (US$ Million)
Figure 13. Global Human Tuberculosis Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 14. Global Human Tuberculosis Vaccine Revenue Market Share by Region (2018-2029)
Figure 15. Global Human Tuberculosis Vaccine Sales 2018-2029 ((K Units)
Figure 16. Global Human Tuberculosis Vaccine Sales Market Share by Region (2018-2029)
Figure 17. US & Canada Human Tuberculosis Vaccine Sales YoY (2018-2029) & (K Units)
Figure 18. US & Canada Human Tuberculosis Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 19. Europe Human Tuberculosis Vaccine Sales YoY (2018-2029) & (K Units)
Figure 20. Europe Human Tuberculosis Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 21. China Human Tuberculosis Vaccine Sales YoY (2018-2029) & (K Units)
Figure 22. China Human Tuberculosis Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Asia (excluding China) Human Tuberculosis Vaccine Sales YoY (2018-2029) & (K Units)
Figure 24. Asia (excluding China) Human Tuberculosis Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales YoY (2018-2029) & (K Units)
Figure 26. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 27. The Human Tuberculosis Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of Human Tuberculosis Vaccine in the World: Market Share by Human Tuberculosis Vaccine Revenue in 2022
Figure 29. Global Human Tuberculosis Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Human Tuberculosis Vaccine Sales Market Share by Type (2018-2029)
Figure 31. Global Human Tuberculosis Vaccine Revenue Market Share by Type (2018-2029)
Figure 32. Global Human Tuberculosis Vaccine Sales Market Share by Application (2018-2029)
Figure 33. Global Human Tuberculosis Vaccine Revenue Market Share by Application (2018-2029)
Figure 34. US & Canada Human Tuberculosis Vaccine Sales Market Share by Type (2018-2029)
Figure 35. US & Canada Human Tuberculosis Vaccine Revenue Market Share by Type (2018-2029)
Figure 36. US & Canada Human Tuberculosis Vaccine Sales Market Share by Application (2018-2029)
Figure 37. US & Canada Human Tuberculosis Vaccine Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada Human Tuberculosis Vaccine Revenue Share by Country (2018-2029)
Figure 39. US & Canada Human Tuberculosis Vaccine Sales Share by Country (2018-2029)
Figure 40. U.S. Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 41. Canada Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 42. Europe Human Tuberculosis Vaccine Sales Market Share by Type (2018-2029)
Figure 43. Europe Human Tuberculosis Vaccine Revenue Market Share by Type (2018-2029)
Figure 44. Europe Human Tuberculosis Vaccine Sales Market Share by Application (2018-2029)
Figure 45. Europe Human Tuberculosis Vaccine Revenue Market Share by Application (2018-2029)
Figure 46. Europe Human Tuberculosis Vaccine Revenue Share by Country (2018-2029)
Figure 47. Europe Human Tuberculosis Vaccine Sales Share by Country (2018-2029)
Figure 48. Germany Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 49. France Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 50. U.K. Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 51. Italy Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 52. Russia Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 53. China Human Tuberculosis Vaccine Sales Market Share by Type (2018-2029)
Figure 54. China Human Tuberculosis Vaccine Revenue Market Share by Type (2018-2029)
Figure 55. China Human Tuberculosis Vaccine Sales Market Share by Application (2018-2029)
Figure 56. China Human Tuberculosis Vaccine Revenue Market Share by Application (2018-2029)
Figure 57. Asia Human Tuberculosis Vaccine Sales Market Share by Type (2018-2029)
Figure 58. Asia Human Tuberculosis Vaccine Revenue Market Share by Type (2018-2029)
Figure 59. Asia Human Tuberculosis Vaccine Sales Market Share by Application (2018-2029)
Figure 60. Asia Human Tuberculosis Vaccine Revenue Market Share by Application (2018-2029)
Figure 61. Asia Human Tuberculosis Vaccine Revenue Share by Region (2018-2029)
Figure 62. Asia Human Tuberculosis Vaccine Sales Share by Region (2018-2029)
Figure 63. Japan Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 64. South Korea Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 65. China Taiwan Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 66. Southeast Asia Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 67. India Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 68. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales Market Share by Type (2018-2029)
Figure 69. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales Market Share by Application (2018-2029)
Figure 71. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Human Tuberculosis Vaccine Revenue Share by Country (2018-2029)
Figure 73. Middle East, Africa and Latin America Human Tuberculosis Vaccine Sales Share by Country (2018-2029)
Figure 74. Brazil Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 75. Mexico Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 76. Turkey Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 77. Israel Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 78. GCC Countries Human Tuberculosis Vaccine Revenue (2018-2029) & (US$ Million)
Figure 79. Human Tuberculosis Vaccine Value Chain
Figure 80. Human Tuberculosis Vaccine Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries